Drug Delivery Research Group

The "Drug Delivery" research group seeks to find creative and innovative solutions to the current challenges limiting the therapeutic efficiency of many drugs such as low solubility, low permeability, low efficacy and high toxicity and resulting in poor patient compliance. We aim to develop novel platforms and smart delivery systems that ensure the effective delivery and tolerability of different marketed and new drugs in order to contribute to the overall enhancement of disease management and human health and to increase the cost effectiveness of such treatments. 

Our drug delivery research group is dedicated to advancing the field by exploring innovative approaches and technologies to overcome the challenges associated with traditional drug delivery methods. We aim to develop targeted and efficient delivery systems that can enhance drug efficacy, minimize side effects, and improve patient outcomes. Our research encompasses a wide range of areas, including nanomedicine, biomaterials, and controlled-release systems. By staying at the forefront of drug delivery research, we strive to contribute to the development of safer, more effective therapies for various diseases and conditions.

• Nano-formulations to enhance the delivery of diagnostic and therapeutic agents
• Novel non-invasive and user-friendly dosage forms and systems to enhance drug delivery and patient compliance 
• Hydrogel scaffolds for controlled drug release and cell-based therapy 
• Polymer-based and lipid-based systems for drug targeting.
• Modeling-based drug development and formulation. 

1. Targeting Breast and Prostate Cancer: Design and Synthesis of Novel and Privileged polycyclic pyrido[1,2-a]quinolinones, Benzopyranes and Benzoxepines Motifs(AJF 201531). PI-Taleb H. AlTel-AlJalila Foundation-266,000AED. 
2. "Effect of Tumor Microrna Secretome before and after cancer chemotherapy on heart and skeletal muscle morphology and function"-PI-Dr. Rafaat El-Awady- funded from Aljalila Foundation-295,000AED. 
3. "OSU-2S Combinatorial Approach, the next level in tackling cancer cell survival" –PI- Dr. Hany A. Omar- funded from Aljalila Foundation-245,000AED. 
4. "Targeted Cancer Drug Design: Selective Targeting of HDACs Using Diversity Oriented Organic Synthesis and In Silico Aided Drug Design Strategies"-PI-Taleb H. AlTel-TerryFox Foundation-127,000AED.
5. "Discovery, Development, and Molecular Mechanism of Novel Inhibitors of Human Hexokinase 2 as Anticancer Therapeutics"- Co-PI-Taleb H. AlTel-NYU-AD- TerryFox Foundation-127,000AED.
6. "Design and Discovery of Lead Drug Candidates: Targeting Alzheimer's and Cancer Diseases"-PI-Taleb H. AlTel; KEF Holding Foundation-100,000AED 
7. "Novel approaches toward the discovery of drugs for the treatment of Diabetes, Obesity and Cancer"-PI-Taleb H. AlTel, NRF-200,000AED.
8. Many Grants for graduate students projects from Boehringer Ingelheim Pharmaceutical Company.